Publication | Open Access
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
78
Citations
19
References
2023
Year
Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii StudyCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology
| Year | Citations | |
|---|---|---|
Page 1
Page 1